文献速递免疫规划

不同基础免疫程序接种蜱传脑炎疫苗后加强免疫至少15年抗体持续存在:第三次5年随访

Sustained antibody persistence for at least 15 years after a booster vaccination against tick-borne encephalitis following different primary vaccination schedules: Third 5-year follow-up.
PubMed 文献 · Vaccine · 2023-05-03

这项IV期、开放标签、单中心扩展研究纳入194名成人,按快速、常规或加速常规基础程序接种蜱传脑炎疫苗后3年加强一剂,每年用中和试验检测抗体至加强后15年。结果显示所有程序组中和抗体滴度≥10的比例在11-15年间保持高位,几何平均滴度在各组及≥50岁、≥60岁人群中均维持较高水平。

要点

  • 加强后11-15年,R组和A组中和抗体滴度≥10的比例均为100%和99.0%,C组从100%(第11年)降至95.8%(第15年)。
  • 三组中和抗体几何平均滴度相似:R组181-267,C组142-227,A组141-209。
  • ≥50岁和≥60岁人群中和抗体几何平均滴度在各组各时间点仍保持较高水平(分别为98-206和91-191)。

核心结论

  • 本研究显示,无论青少年或成人接受何种基础免疫程序,接种Encepur Adults蜱传脑炎疫苗后首次加强免疫至少15年内中和抗体持续存在,所有评估年龄组均如此。

研究设计与样本

  • IV期、开放标签、单中心扩展研究,纳入194名成人并纳入符合方案集,188名完成研究。
  • 受试者在≥12岁时按随机分配的三种蜱传脑炎疫苗基础程序之一(快速组R、常规组C、加速常规组A)接种,3年后加强一剂。
  • 加强后11至15年每年用蜱传脑炎病毒中和试验检测抗体,中和试验滴度≥10视为有临床意义的保护替代阈值。

主要发现

  • 中和试验滴度≥10的参与者比例:R组和A组在所有访视均为100%和99.0%,C组从100%(第11年)降至95.8%(第15年)。
  • 中和试验几何平均滴度三组相似:R组181-267,C组142-227,A组141-209。
  • ≥50岁人群中和试验几何平均滴度在各组各时间点为98-206,≥60岁人群为91-191。

关键数值与推荐

  • 中和试验滴度≥10被定为有临床意义的阈值和保护替代指标。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Vaccination is the best mode of protection against tick-borne encephalitis (TBE) and its sequelae. The duration of protection and the optimal interval of repeat booster doses are still debated. The current study evaluated the persistence of the antibody response 11-15 years after a first booster vaccination following different primary vaccination schedules with a TBE vaccine (Encepur Adults, manufactured by Bavarian Nordic, previously by GSK). METHODS: This phase IV, open-label, mono-centric extension study enrolled adults who had received (at ≥ 12 years of age) primary vaccination with one of three randomly assigned TBE vaccine schedules (rapid [group R], conventional [group C], or accelerated conventional schedule [group A]) followed by a booster dose 3 years later. The antibody response was measured annually from 11 to 15 years post-booster using a TBE virus neutralization test (NT). An NT titer of ≥ 10 was considered as a clinically meaningful threshold and surrogate for protection. RESULTS: In total, 194 participants were enrolled and included in the per-protocol set; 188 completed the study. The percentage of participants with an NT titer ≥ 10 was 100% in group R and 99.0% in group A at all visits and ranged from 100% (year 11) to 95.8% (year 15) in group C. NT geometric mean titers were similar in the three study groups (181-267 in group R, 142-227 in group C, 141-209 in group A). NT geometric mean titers also remained high among participants ≥ 50 years old (98-206) and ≥ 60 years old (91-191) across study groups and time points. CONCLUSIONS: This study showed neutralizing antibody persistence for at least 15 years after a first booster dose of the Encepur Adults TBE vaccine in all age groups evaluated, regardless of which primary vaccination schedule was given to adolescents or adults. Trialregistry: ClinicalTrials.gov: NCT03294135.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Beran J, Lattanzi M, Costantini M, et al. Sustained antibody persistence for at least 15 years after a booster vaccination against tick-borne encephalitis following different primary vaccination schedules: Third 5-year follow-up. Vaccine. 2023. PMID: 37142462. doi:10.1016/j.vaccine.2023.04.061

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。